Credit: Shutterstock
February 1, 2024 07:00 AM ESTUpdated 08:06 AM
Bioregnum

Biotech deal­mak­ing shows some signs of a turn­around. And the in­dus­try is keep­ing its fin­gers crossed

John Carroll

Editor & Founder

The big pan­dem­ic boom that fu­eled some crazy num­bers in biotech is long gone, as any­one in the in­dus­try who doesn’t re­side in a sen­so­ry …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times